Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Inherit Metab Dis ; 30(6): 978, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17876719

ABSTRACT

From 1 January 2007 an expanded neonatal screening programme was initiated in the Netherlands, including homocystinuria with methionine as the primary marker. During the first 2 months hypermethioninaemia was detected in 14 newborns who, after proper evaluation, were demonstrated not to have classical homocystinuria. Remarkably, all these children were admitted to a single neonatal intensive care unit (Academic Medical Center, Amsterdam (AMC-NICU)). We evaluated the possible causes for this finding. The cohort of newborns with hypermethioninaemia (group 1) was compared with the cohort of newborns with normal screening results admitted to the AMC-NICU in the same time period (group 2). In addition, parenteral nutrition protocols from all NICUs in the Netherlands were compared. Mean birth weight and gestational age were significantly lower in group 1 than in group 2. All patients in group 1 received parenteral feeding (TPN) at the time of screening and received a higher mean amino acid intake per kilogram body weight than patients receiving TPN in group 2. Also, the AMC-NICU uses a different amino acid mixture for TPN than the other Dutch NICUs, containing more than twice the amount of methionine per gram of amino acids compared with other mixtures. The high incidence of hypermethioninaemia in the AMC-NICU is explained by a combination of low birth weight, low gestational age, and high protein intake supplied by a specific parenteral amino acid mixture containing large amounts of methionine. To prevent hypermethioninaemia, the use of high-methionine containing solutions for TPN should be reconsidered.


Subject(s)
Amino Acid Metabolism, Inborn Errors/diagnosis , Amino Acid Metabolism, Inborn Errors/epidemiology , Homocystinuria/diagnosis , Homocystinuria/epidemiology , Intensive Care, Neonatal/methods , Methionine/metabolism , Amino Acids/therapeutic use , Birth Weight , Cohort Studies , Gestational Age , Humans , Incidence , Infant, Newborn , Intensive Care Units, Neonatal , Methionine/chemistry , Neonatal Screening , Netherlands
2.
Epilepsy Res ; 59(2-3): 75-82, 2004.
Article in English | MEDLINE | ID: mdl-15246112

ABSTRACT

RATIONALE: Altered expression of glutamate transporter EAAT2 protein has been reported in the hippocampus of patients with temporal lobe epilepsy (TLE). Two alternative EAAT2 mRNA splice forms, one resulting from a partial retention of intron 7 (I7R), the other from a deletion of exon 9 (E9S), were previously implicated in the loss of EAAT2 protein in patients with amyotrophic lateral sclerosis. METHODS: By RT-PCR we studied the occurrence of I7R and E9S in neocortical and hippocampal specimens from TLE patients and non-neurological controls. RESULTS: Both splice forms were found in all neocortical specimens from TLE patients (100% I7R, 100% E9S). This was significantly more than in controls (67% I7R, 60% E9S; P < 0.05). We also detected I7R and E9S in all seven motor cortex post-mortem samples from patients with amyotrophic lateral sclerosis. Within the TLE patient group, both splice variants appeared significantly more in non-sclerotic (100%), than in sclerotic hippocampi (69%, P < 0.05). CONCLUSION: These data indicate that the epileptic brain, especially that of TLE patients without hippocampal sclerosis, is highly prone to alternative EAAT2 mRNA splicing. Our data confirm that the presence of alternative EAAT2 splice forms is not disease specific.


Subject(s)
Alternative Splicing/genetics , Epilepsy, Temporal Lobe/genetics , Excitatory Amino Acid Transporter 2/genetics , Hippocampus/metabolism , Neocortex/metabolism , RNA, Messenger/metabolism , Adult , Aged , Alternative Splicing/physiology , Chi-Square Distribution , Epilepsy, Temporal Lobe/metabolism , Excitatory Amino Acid Transporter 2/metabolism , Humans , Middle Aged , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/genetics
3.
Mol Psychiatry ; 8(9): 786-96, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12931206

ABSTRACT

Glial fibrillary acidic protein (GFAP) is considered to be a highly specific marker for glia. Here, we report on the expression of GFAP in neurons in the human hippocampus. Intriguingly, this neuronal GFAP is coded by out-of-frame splice variants and its expression is associated with Alzheimer pathology. We identified three novel GFAP splice forms: Delta 135 nt, Delta exon 6 and Delta 164 nt. Neuronal GFAP is mainly observed in the pyramidal neurons of the hippocampus of Alzheimer and Down syndrome patients and aged controls, but not in neurons of patients suffering from hippocampal sclerosis. Apparently, the hippocampal neurons in patients with Alzheimer's disease pathology are capable of expressing glia-specific genes.


Subject(s)
Alternative Splicing , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Frameshifting, Ribosomal , Glial Fibrillary Acidic Protein/metabolism , Neurons/metabolism , Transcription, Genetic , Alzheimer Disease/genetics , Amino Acid Sequence , Base Sequence , Down Syndrome/genetics , Down Syndrome/metabolism , Down Syndrome/pathology , Epilepsy, Temporal Lobe/genetics , Epilepsy, Temporal Lobe/pathology , Epilepsy, Temporal Lobe/physiopathology , Exons , Female , Glial Fibrillary Acidic Protein/genetics , Hippocampus/metabolism , Hippocampus/pathology , Humans , Male , Molecular Sequence Data , Neuroglia/metabolism , Neuroglia/pathology , Neurons/pathology , RNA, Messenger/analysis , Reading Frames/genetics , Sclerosis
4.
Brain ; 125(Pt 1): 32-43, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11834591

ABSTRACT

In patients suffering from temporal lobe epilepsy (TLE), increased extracellular glutamate levels in the epileptogenic hippocampus both during and after clinical seizures have been reported. These increased glutamate levels could be the result of malfunctioning and/or downregulation of glutamate transporters (also known as EAATs; excitatory amino acid transporters). In this study, the distribution of protein and mRNA of EAAT subtypes was examined in the hippocampus of TLE patients with hippocampal sclerosis (HS group) and without hippocampal sclerosis (non-HS group), and in autopsy controls without neurological disorders. EAAT protein localization was studied by immunohistochemistry on paraffin sections using specific poly- and monoclonal antibodies against the glial glutamate transporters EAAT1 and EAAT2 and the neuronal glutamate transporter EAAT3. Antibody specificity was shown by immunoblotting. In the HS group, a small decrease in EAAT1-immunoreactivity (IR) was observed in CA4 and in the polymorphic and supragranular layer of the dentate gyrus, compared with the control group. The strongest changes were found for EAAT2 levels. In the non-HS group, increased EAAT2-IR was detected in the CA1 and CA2 field, compared with non-epileptic controls. EAAT2-IR was decreased in the HS compared with the non-HS group. Fewer EAAT3-positive cells were found in the HS group than in the non-HS and control group. In both TLE groups, increased EAAT3 levels were observed in individual neurones. In the HS group, the percentage of EAAT3-IR neurones was increased in CA2 and in the granule cell layer of the dentate gyrus. Radioactive in situ hybridization for EAAT1-3 confirmed our immunohistochemical results. Non-radioactive in situ hybridization showed that not only astrocytes, but also neurones express EAAT2 mRNA. Taken together, differences in both mRNA and protein levels of glutamate transporter subtypes were found in specific regions in the TLE hippocampus, with most severe changes found for EAAT2 and EAAT3 levels. The results indicate an upregulation of EAAT2 protein expression in CA1 and CA2 in neurones in the non-HS group. This is in line with decreased EAAT2 protein levels in the HS group, since these hippocampi are characterized by severe neuronal cell loss. The functional consequences (glutamate transport capacity) of the reported changes in EAAT2 and EAAT3 remain to be determined.


Subject(s)
Amino Acid Transport System X-AG/metabolism , Epilepsy, Temporal Lobe/metabolism , Glutamic Acid/metabolism , Hippocampus/metabolism , Adult , Amino Acid Transport System X-AG/genetics , Analysis of Variance , Animals , Anticonvulsants/therapeutic use , Drug Resistance , Epilepsy, Temporal Lobe/drug therapy , Epilepsy, Temporal Lobe/physiopathology , Female , Hippocampus/pathology , Humans , Immunoblotting , Immunohistochemistry , In Situ Hybridization , Male , Middle Aged , Sclerosis
5.
Acta Neuropathol ; 101(4): 405-9, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11355312

ABSTRACT

In patients suffering from temporal lobe epilepsy (TLE) a highly variable degree of hippocampal sclerosis (HS) can be observed. For standard neuropathological evaluation after hippocampal resection, neuronal cell loss in the hippocampal subareas is assessed (Wyler score 0-4) [Wyler et al. (1992) J Epilepsy 5: 220-225]. Other marked morphological changes in the sclerotic hippocampus are gliosis and loss of mossy fibers in the hilus and mossy fiber sprouting in the supragranular layer. In this study we quantified changes in mossy fiber density using Timm's stain in resected hippocampal tissue from patients with various degrees of sclerosis. We found that tissue specimens from patients without sclerosis (W0) show almost no mossy fiber sprouting. Patients with moderate sclerosis show sprouting without fiber loss in the hilus, whereas specimens from patients with severe sclerosis show sprouting as well as fiber loss in the hilus. Thus, analysis of mossy fiber abundance in hilus and supragranular layer by the rapid and simple Timm's stain is a sensitive measure for hippocampal sclerosis. It provides a reliable rapid tool for neuropathological evaluation, even if the tissue only contains dentate gyrus due to the sectioning procedure.


Subject(s)
Epilepsy, Temporal Lobe/pathology , Hippocampus/pathology , Mossy Fibers, Hippocampal/ultrastructure , Severity of Illness Index , Axons/ultrastructure , Biopsy , Gliosis/pathology , Humans , Sclerosis
6.
Brain ; 123 ( Pt 1): 19-30, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10611117

ABSTRACT

Hippocampal sclerosis (HS) is a common derangement in many patients with temporal lobe epilepsy. As a result of neuronal cell loss in the hilar region of the hippocampus, it is proposed that mossy fibres sprout and re-innervate new regions of the dentate gyrus. This sprouting may cause recurrent excitation that may lead to the generation of seizures. Here, we determined neuronal density, and synaptophysin and glial fibrillary acidic protein (GFAP) immunoreactivity in hippocampal specimens from patients with pharmaco-resistant temporal lobe epilepsy. Patients were classified into two groups: those with severe and those with no HS. Non-epileptic autopsy tissue served as controls. Mossy fibre sprouting was investigated in these two groups of epilepsy patients using Timm's staining and an immunohistochemical staining of the presynaptic growth-associated protein B-50 (also known as GAP-43, neuromodulin, F1). B-50 immunoreactivity in the different sub-areas of the hippocampus was quantified by image analysis. Our results show the following: (i) in both groups of temporal lobe epilepsy patients, there was a significant loss in cell number in all major hippocampal sub-areas compared with autopsy control tissue; (ii) in HS patients, when compared with non-HS patients, there was a further decline in the number of principal cells in all hippocampal sub-areas analysed, which was associated with an increase in GFAP immunoreactivity; (iii) the decline in cell density was accompanied by a reduced number of synaptic terminals; (iv) in the HS group, there were sprouted mossy fibres in the supragranular layer (SGL) of the dentate gyrus; (v) there was an increase in synaptophysin immunostaining in the SGL indicating that functionally active nerve terminals were formed; and (vi) B-50 immunoreactivity was also increased in the SGL in the HS group compared with the non-HS and control groups. These data showed that all temporal lobe epilepsy hippocampi investigated had severe neuronal cell loss which was most dramatic in the HS group, where it was accompanied by a severe loss of synapses. In the HS group, mossy fibre sprouting into the SGL was found. The increase in B-50 immunoreactivity in the SGL indicated that there was still active sprouting. This sprouting was accompanied by an increased density of synapses, indicating that mossy fibre terminals are not only anatomically present, but probably also functional. Thus, functional glutamatergic mossy fibre terminals are in the right position to synapse on to the dendrites of granule cells and thus may contribute to the onset of seizures.


Subject(s)
Epilepsy, Temporal Lobe/pathology , Hippocampus/pathology , Mossy Fibers, Hippocampal/pathology , Adolescent , Adult , Autopsy , Child, Preschool , Dentate Gyrus/pathology , Drug Resistance , Epilepsy, Temporal Lobe/surgery , Female , GAP-43 Protein/analysis , Glial Fibrillary Acidic Protein/analysis , Humans , Immunohistochemistry , Male , Middle Aged , Neurons/pathology , Reference Values , Synaptophysin/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...